Epidemiologist Erin Bowles, MPH, is looking at cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Health Care Systems Cancer Research Network (CRN) — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of care in cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20 years has provided her with expertise in data collection and quality control for many subject areas. She is also a manager of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to junior faculty.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Fernandes-Taylor S, Bowles EJA, Venkatesh M, Doud R, Krebsbach C, Arroyo N, Hanlon B, Chen AY, Davies L, Francis DO. Differential ultrasound rates mirror sex disparities in thyroid cancer. Thyroid. 2024 Nov 28. doi: 10.1089/thy.2024.0344. Online ahead of print. PubMed
Foster VM, Trentham-Dietz A, Stout NK, Lee CI, Ichikawa LE, Eavey J, Henderson L, Miglioretti DL, Tosteson ANA, Bowles EA, Kerlikowske K, Sprague BL. Supplemental breast cancer screening after negative mammography in U.S. women with dense breasts. J Natl Cancer Inst. 2024 Oct 30:djae272. doi: 10.1093/jnci/djae272. [Epub ahead of print]. PubMed
Miglioretti DL, Abraham L, Sprague BL, Lee CI, Bissell MCS, Ho TH, Bowles EJA, Henderson LM, Hubbard RA, Tosteson ANA, Kerlikowske K. Association between false-positive results and return to screening mammography in the Breast Cancer Surveillance Consortium cohort. Ann Intern Med. 2024 Sep 3. doi: 10.7326/M24-0123. Online ahead of print. PubMed
Bhimani J, O'Connell K, Persaud S, Blinder V, Burganowski RP, Ergas IJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, Aiello Bowles EJ, Kushi LH, Kantor ED. The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system. Breast Cancer Res Treat. 2024 Aug 16. doi: 10.1007/s10549-024-07433-4. [Epub ahead of print]. PubMed
Aiello Bowles EJ, Ramin C, Vo JB, Feigelson HS, Gander JC, Veiga LHS, Bodelon C, Curtis RE, Brandt C, Berrington de Gonzalez A, Gierach GL. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001-2018. Breast Cancer Res Treat. 2024 Aug 16. doi: 10.1007/s10549-024-07453-0. Online ahead of print. PubMed
Bhimani J, O’Connell K, Persaud S, Blinder V, Burganowski R, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, Bowles EJA, Kushi LH, Kantor ED. Patient characteristics associated with intended non-guideline chemotherapy in women with stage I-IIIA breast cancer. Cancer Epidemiol Biomarkers Prev. 2024 Jul 25. doi: 10.1158/1055-9965.EPI-24-0360. Online ahead of print. PubMed
New study will develop risk models to improve clinical guidelines and practice.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
The division contributes to research across the institute with methodological and subject matter expertise.
How KPWHRI is contributing to better cancer screening and better outcomes for patients.
Cell by cell, scientists are building a high-resolution map of brain changes in Alzheimer’s disease.